<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-id journal-id-type="hwp">ahaoa</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28400368</article-id><article-id pub-id-type="pmc">5533023</article-id><article-id pub-id-type="doi">10.1161/JAHA.116.005334</article-id><article-id pub-id-type="publisher-id">JAH32181</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Coronary Heart Disease</subject></subj-group></subj-group></article-categories><title-group><article-title>Relationship Between Peak Troponin Values and Long&#x02010;Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes</article-title><alt-title alt-title-type="left-running-head">Goldstein et&#x000a0;al</alt-title></title-group><contrib-group><contrib id="jah32181-cr-0001" contrib-type="author"><name><surname>Goldstein</surname><given-names>Sarah A.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32181-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jah32181-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah32181-cr-0002" contrib-type="author" corresp="yes"><name><surname>Newby</surname><given-names>L. Kristin</given-names></name><degrees>MD, MHS</degrees><address><email>kristin.newby@duke.edu</email></address><xref ref-type="aff" rid="jah32181-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jah32181-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah32181-cr-0003" contrib-type="author"><name><surname>Cyr</surname><given-names>Derek D.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="jah32181-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32181-cr-0004" contrib-type="author"><name><surname>Neely</surname><given-names>Megan</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="jah32181-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32181-cr-0005" contrib-type="author"><name><surname>L&#x000fc;scher</surname><given-names>Thomas F.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32181-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jah32181-cr-0006" contrib-type="author"><name><surname>Brown</surname><given-names>Eileen B.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32181-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jah32181-cr-0007" contrib-type="author"><name><surname>White</surname><given-names>Harvey D.</given-names></name><degrees>MB, ChB, DSc</degrees><xref ref-type="aff" rid="jah32181-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jah32181-cr-0008" contrib-type="author"><name><surname>Ohman</surname><given-names>E. Magnus</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32181-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jah32181-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah32181-cr-0009" contrib-type="author"><name><surname>Roe</surname><given-names>Matthew T.</given-names></name><degrees>MD, MHS</degrees><xref ref-type="aff" rid="jah32181-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jah32181-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah32181-cr-0010" contrib-type="author"><name><surname>Hamm</surname><given-names>Christian W.</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32181-aff-0006">
<sup>6</sup>
</xref></contrib></contrib-group><aff id="jah32181-aff-0001">
<label><sup>1</sup></label>
<institution>Duke Clinical Research Institute</institution>
<named-content content-type="city">Durham</named-content>
<named-content content-type="country-part">NC</named-content>
</aff><aff id="jah32181-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Division of Cardiology</named-content>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>Duke University Medical Center</institution>
<named-content content-type="city">Durham</named-content>
<named-content content-type="country-part">NC</named-content>
</aff><aff id="jah32181-aff-0003">
<label><sup>3</sup></label>
<institution>University Hospital Zurich</institution>
<named-content content-type="city">Zurich</named-content>
<country country="CH">Switzerland</country>
</aff><aff id="jah32181-aff-0004">
<label><sup>4</sup></label>
<institution>Eli Lilly and Company</institution>
<named-content content-type="city">Indianapolis</named-content>
<named-content content-type="country-part">IN</named-content>
</aff><aff id="jah32181-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Green Lane Cardiovascular Service</named-content>
<institution>Auckland City Hospital</institution>
<named-content content-type="city">Auckland</named-content>
<country country="NZ">New Zealand</country>
</aff><aff id="jah32181-aff-0006">
<label><sup>6</sup></label>
<institution>University of Giessen</institution>
<country country="DE">Germany</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> L. Kristin Newby, MD, MHS, Duke Clinical Research Institute, P.O. Box&#x000a0;17969, Durham, NC 27715&#x02010;7969. E&#x02010;mail: <email>kristin.newby@duke.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2017</year></pub-date><volume>6</volume><issue>4</issue><issue-id pub-id-type="doi">10.1002/jah3.2017.6.issue-4</issue-id><elocation-id>e005334</elocation-id><history><date date-type="received"><day>13</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>10</day><month>3</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-6-e005334.pdf"/><abstract id="jah32181-abs-0001"><sec id="jah32181-sec-0001"><title>Background</title><p>The relationship between troponin level and outcomes among patients with non&#x02010;<styled-content style="fixed-case">ST</styled-content>&#x02010;segment elevation ACS is established, but the relationship of troponin level with long&#x02010;term outcomes among medically managed non&#x02010;ST&#x02010;segment elevation ACS patients receiving contemporary antiplatelet therapy is inadequately defined.</p></sec><sec id="jah32181-sec-0002"><title>Methods and Results</title><p>In 6763 medically managed non&#x02010;ST&#x02010;segment elevation ACS patients randomized in <styled-content style="fixed-case">TRILOGY ACS</styled-content> (Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes) (prasugrel versus clopidogrel), we examined relationships between categories of peak troponin/upper limit of normal (<styled-content style="fixed-case">ULN</styled-content>) ratio within 48&#x000a0;hours of the index <styled-content style="fixed-case">ACS</styled-content> event (&#x02248;4.5&#x000a0;days before randomization) and 30&#x02010;month outcomes (cardiovascular death, myocardial infarction, or stroke; cardiovascular death or myocardial infarction; and all&#x02010;cause death). Patients with peak troponin levels &#x0003c;1&#x000d7;<styled-content style="fixed-case">ULN</styled-content> were younger, were more often women, and had lower <styled-content style="fixed-case">GRACE</styled-content> risk scores than those in other troponin groups. Those with ratios &#x02265;5&#x000d7;<styled-content style="fixed-case">ULN</styled-content> were more frequently smokers but less often had prior myocardial infarction or percutaneous coronary intervention. Diabetes mellitus prevalence, body mass index, serum creatinine, and hemoglobin were similar across groups. For all end points, statistically significant differences in 30&#x02010;month event rates were observed between peak troponin categories. The relationship was linear for 30&#x02010;month mortality (&#x0003c;1&#x000d7;<styled-content style="fixed-case">ULN</styled-content>, n=1849 [6.2%]; 1 to &#x0003c;3&#x000d7;<styled-content style="fixed-case">ULN</styled-content>, n=1203 [9.6%]; 3 to &#x0003c;5&#x000d7;<styled-content style="fixed-case">ULN</styled-content>, n=581 [10.8%]; and &#x02265;5&#x000d7;<styled-content style="fixed-case">ULN</styled-content>, n=3405 [12.8%]) but plateaued for composite end points beyond peak troponin values &#x02265;3&#x000d7;<styled-content style="fixed-case">ULN</styled-content>. There was no statistically significant heterogeneity in treatment effect by peak troponin ratio for any end point.</p></sec><sec id="jah32181-sec-0003"><title>Conclusions</title><p>Among medically managed non&#x02010;ST&#x02010;segment elevation ACS patients selected for medical management, there was a graded relationship between increasing peak troponin and long&#x02010;term ischemic events but no heterogeneity of treatment effect for prasugrel versus clopidogrel according to peak troponin.</p></sec><sec id="jah32181-sec-0004"><title>Clinical Trial Registration</title><p>
<styled-content style="fixed-case">URL</styled-content>: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>. Unique identifier: <styled-content style="fixed-case">NCT</styled-content>00699998.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah32181-kwd-0001">acute coronary syndromes</kwd><kwd id="jah32181-kwd-0002">myocardial infarction</kwd><kwd id="jah32181-kwd-0003">risk stratification</kwd><kwd id="jah32181-kwd-0004">troponin</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Acute Coronary Syndromes</kwd></kwd-group><funding-group><award-group><funding-source>Daiichi Sankyo Incorporated</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Eli Lilly and Company</funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="3"/><page-count count="10"/><word-count count="6768"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jah32181</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.3 mode:remove_FC converted:11.07.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jah32181-cit-1001">(<source>J Am Heart Assoc</source>. <year>2017</year>;<volume>6</volume>:<elocation-id>e005334</elocation-id> DOI:<ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.116.005334">10.1161/JAHA.116.005334</ext-link>.)<pub-id pub-id-type="pmid">28400368</pub-id></mixed-citation>
</p></notes></front><body><sec id="jah32181-sec-0005"><title>Introduction</title><p>The relationship between baseline levels of troponin or creatine kinase&#x02010;MB and outcomes among patients with non&#x02010;ST&#x02010;segment elevation acute coronary syndromes (NSTE ACS) is established.<xref rid="jah32181-bib-0001" ref-type="ref">1</xref> This relationship has not been well studied in medically managed NSTE ACS populations in the era of modern antithrombotic therapy that includes systematic use of more potent P2Y12 inhibition as a component of dual antiplatelet therapy. In addition, whether the effect of treatment with a more potent P2Y12 antagonist (eg, prasugrel versus clopidogrel) is influenced by degree of biomarker elevation, particularly among medically managed patients, is unknown. Although the relationship of troponin elevation at baseline with outcome is strong over the first 30&#x000a0;days post&#x02010;ACS, it becomes weaker over longer durations of follow&#x02010;up.<xref rid="jah32181-bib-0002" ref-type="ref">2</xref>, <xref rid="jah32181-bib-0003" ref-type="ref">3</xref> The TRILOGY ACS (Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes) trial database provided the opportunity to explore these important issues in a medically managed NSTE ACS population treated with long&#x02010;term dual antiplatelet therapy.</p><p>In a substudy of TRILOGY ACS, the Platelet Function Substudy, evaluation of platelet reactivity measured by serial P2Y12 reaction unit (PRU) assessment showed more potent platelet inhibition with prasugrel compared with clopidogrel.<xref rid="jah32181-bib-0004" ref-type="ref">4</xref> There was no relationship between platelet reactivity and ischemic outcomes or differential treatment effect according to platelet reactivity. The relationship between peak troponin level, platelet reactivity, outcomes, and treatment effect has not been explored. The Platelet Function Substudy provided an opportunity to examine these relationships.</p></sec><sec id="jah32181-sec-0006"><title>Methods</title><sec id="jah32181-sec-0007"><title>Data Source</title><p>The study design and primary results of TRILOGY ACS were previously published.<xref rid="jah32181-bib-0005" ref-type="ref">5</xref> Briefly, TRILOGY ACS was a multinational, double&#x02010;blind, double&#x02010;dummy, randomized active controlled trial that compared the effects of prasugrel versus clopidogrel among patients with NSTE ACS who were medically managed without revascularization. The trial was conducted between June 2008 and September 2011 at 966 centers worldwide. The primary end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction (MI), or nonfatal stroke at 30&#x02010;month follow&#x02010;up. The trial was approved by the institutional review board or ethics committee of all participating sites, and all participants provided written informed consent prior to enrollment. The current analyses were approved by the Duke University Medical Center Institutional Review Board with waiver of informed consent and HIPAA (Health Insurance Portability and Accountability Act of 1996) authorization.</p></sec><sec id="jah32181-sec-0008"><title>Patient Characteristics and Study Definitions</title><p>TRILOGY ACS randomized 9326 patients. For this secondary analysis, we identified 6763 patients (72.5% of the intention&#x02010;to&#x02010;treat population) for whom peak troponin (T or I) data were available within 48&#x000a0;hours of the index event. Troponin I was used twice as often as troponin T. Patients were excluded if they had recurrent MI, bypass surgery, or percutaneous coronary intervention between the index event presentation and the reported peak cardiac troponin value. The analysis of platelet function included only patients enrolled in the Platelet Function Substudy who had peak troponin data available (n=1810/2564 [70.6%]).</p></sec><sec id="jah32181-sec-0009"><title>End Points</title><p>Efficacy outcomes of interest in this secondary analysis were the following: (1) 30&#x02010;month cardiovascular death, MI, or stroke (primary efficacy end point of TRILOGY ACS); (2) 30&#x02010;month cardiovascular death or MI; (3) 30&#x02010;month rates of the individual components cardiovascular death, MI, and stroke; and (4) 30&#x02010;month all&#x02010;cause death.</p></sec><sec id="jah32181-sec-0010"><title>Statistical Methods</title><p>Because multiple troponin assays were used across the 966 sites in TRILOGY ACS, we normalized site&#x02010;laboratory&#x02010;based peak troponin values as a ratio of the site&#x02010;reported upper limit of normal (ULN) for the assay used. Patients were grouped by categories of peak troponin/ULN ratio (&#x0003c;1&#x000d7;ULN; 1 to &#x0003c;3&#x000d7;ULN; 3 to &#x0003c;5&#x000d7;ULN; &#x02265;5&#x000d7;ULN). Peak troponin ratios were truncated to the 98th percentile for statistical analysis. For this study, peak troponin was the highest value measured within 48&#x000a0;hours of the index event.</p><p>Baseline patient characteristics, including demographics, clinical characteristics, GRACE (Global Registry of Acute Coronary Events) risk score, and concomitant medications at randomization, were summarized according to peak troponin ratio. The GRACE score is a risk&#x02010;stratification tool developed to estimate the risk of in&#x02010;hospital and 6&#x02010;month mortality among all patients hospitalized with ACS. The risk score was created from a risk&#x02010;prediction model developed using an international ACS registry database.<xref rid="jah32181-bib-0006" ref-type="ref">6</xref> Continuous variables are presented as medians (25th, 75th percentiles), and differences were compared using the Kruskal&#x02013;Wallis test. Categorical variables are presented as counts (percentages), and differences were compared using the Pearson &#x003c7;<sup>2</sup> or Fisher exact test if cell frequencies were not sufficient.</p><p>For each ischemic outcome, the total number of events and Kaplan&#x02013;Meier event rates at 30&#x000a0;months after randomization (95% CI) were presented according to peak troponin category. Time&#x02010;to&#x02010;event is defined as the time from randomization to the onset of the end point. Time&#x02010;to&#x02010;first&#x02010;event for a composite end point is defined as the time from randomization to the occurrence of the first event of the composite end point. Censoring rules are defined in Tables <xref rid="jah32181-sup-0001" ref-type="supplementary-material">S1</xref> and <xref rid="jah32181-sup-0001" ref-type="supplementary-material">S2</xref>. Event rates across the follow&#x02010;up period were compared using the log&#x02010;rank test.</p><p>To examine the relationship between peak troponin level and clinical outcomes, unadjusted and adjusted Cox proportional hazards regression models were developed to test the univariable and multivariable associations of continuous peak troponin ratios with each clinical outcome. TRILOGY ACS models previously built for each ischemic outcome were used to adjust for baseline characteristics and risk factors. The proportional hazards assumption was checked for each variable, and the linearity assumption was checked for each continuous variable. If the proportional hazards assumption was violated, an interaction of the variable with log&#x02010;transformed time was included in the model. If the linearity assumption was violated, a linear or restricted cubic spline was used to approximate the nonlinear relationship of the variable with the outcome.<xref rid="jah32181-bib-0007" ref-type="ref">7</xref> In cases where the peak troponin ratio was found to have a nonlinear relationship with a given end point, it was modeled using a linear spline with a knot point at 3.0&#x000d7;ULN, which was determined via numerical simulation across the range of all peak troponin ratios. For further details, please see Table&#x000a0;<xref rid="jah32181-sup-0001" ref-type="supplementary-material">S3</xref>. A full description of the TRILOGY ACS adjustment models used in this analysis is provided in Data <xref rid="jah32181-sup-0001" ref-type="supplementary-material">S1</xref> and Table&#x000a0;<xref rid="jah32181-sup-0001" ref-type="supplementary-material">S4</xref>.</p><p>The interaction between peak troponin level, study treatment (prasugrel versus clopidogrel), and ischemic outcomes was also computed. Further assessment of this relationship was completed in a subgroup of patients who underwent coronary angiography prior to randomization, eliminating those without angiographically proven coronary disease (lesion causing &#x0003e;50% stenosis).</p><p>Baseline characteristics of patients in the Platelet Function Substudy sample were summarized according to peak troponin ratio category. For these patients, the unadjusted and adjusted associations of peak troponin ratio with 30&#x02010;day PRU values and the interaction with study treatment were evaluated. To gauge the strength of the linear relationship between peak troponin ratio and 30&#x02010;day PRU values, the Pearson correlation coefficient was computed and the null hypothesis of zero correlation was tested.</p><p>All analyses were conducted using SAS statistical software version 9.4 (SAS Institute, Cary, NC). A <italic>P</italic> value of &#x0003c;0.05 (2&#x02010;sided) was considered statistically significant. No adjustments were made for multiple comparisons.</p></sec></sec><sec id="jah32181-sec-0011"><title>Results</title><sec id="jah32181-sec-0012"><title>Overall Study Sample</title><p>Baseline characteristics of the 6763 patients who had sufficient laboratory data reported to determine the peak troponin ratio at 48&#x000a0;hours compared with the 2563 patients who were excluded are provided in Table&#x000a0;<xref rid="jah32181-sup-0001" ref-type="supplementary-material">S5</xref>. Baseline characteristics of the 6763 patients included are shown by peak troponin ratio categories in Table&#x000a0;<xref rid="jah32181-tbl-0001" ref-type="table-wrap">1</xref>. Patients with peak troponin ratios &#x0003c;1&#x000d7;ULN were younger, more often women, more often from Central/Eastern Europe, and had lower GRACE risk scores than patients in other troponin groups. Patients with ratios &#x02265;5&#x000d7;ULN more frequently smoked but less often had prior MI or percutaneous coronary intervention. Diabetes mellitus prevalence, body mass index, and hemoglobin were similar across groups. Although there was a statistically significant difference in serum creatinine across troponin groups, absolute differences were small and unlikely to be clinically relevant.</p><table-wrap id="jah32181-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline Characteristics According to 48&#x02010;Hour Peak Troponin Level</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Peak Troponin Level as Ratio of ULN</th><th align="left" rowspan="2" valign="top" colspan="1">
<italic>P</italic> Value</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">&#x0003c;1x (N=1574)</th><th align="left" valign="top" rowspan="1" colspan="1">1x to &#x0003c;3x (N=1203)</th><th align="left" valign="top" rowspan="1" colspan="1">3x to &#x0003c;5x (N=581)</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;5x (N=3405)</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">Demographics</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age, y</td><td align="left" rowspan="1" colspan="1">65.0 (58.0, 72.0)</td><td align="left" rowspan="1" colspan="1">67.0 (58.0, 75.0)</td><td align="left" rowspan="1" colspan="1">67.0 (60.0, 75.0)</td><td align="left" rowspan="1" colspan="1">67.0 (60.0, 76.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age &#x02265;75&#x000a0;y</td><td align="left" rowspan="1" colspan="1">285/1574 (18.1%)</td><td align="left" rowspan="1" colspan="1">301/1203 (25.0%)</td><td align="left" rowspan="1" colspan="1">156/581 (26.9%)</td><td align="left" rowspan="1" colspan="1">954/3405 (28.0%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Weight, kg</td><td align="left" rowspan="1" colspan="1">75.0 (65.0, 86.0)</td><td align="left" rowspan="1" colspan="1">75.0 (65.0, 89.0)</td><td align="left" rowspan="1" colspan="1">75.0 (65.0, 86.0)</td><td align="left" rowspan="1" colspan="1">77.0 (66.0, 89.0)</td><td align="left" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Weight &#x0003c;60&#x000a0;kg</td><td align="left" rowspan="1" colspan="1">211/1573 (13.4%)</td><td align="left" rowspan="1" colspan="1">191/1201 (15.9%)</td><td align="left" rowspan="1" colspan="1">78/581 (13.4%)</td><td align="left" rowspan="1" colspan="1">426/3401 (12.5%)</td><td align="left" rowspan="1" colspan="1">0.033</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">648/1574 (41.2%)</td><td align="left" rowspan="1" colspan="1">466/1203 (38.7%)</td><td align="left" rowspan="1" colspan="1">223/581 (38.4%)</td><td align="left" rowspan="1" colspan="1">1221/3405 (35.9%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">926/1574 (58.8%)</td><td align="left" rowspan="1" colspan="1">737/1203 (61.3%)</td><td align="left" rowspan="1" colspan="1">358/581 (61.6%)</td><td align="left" rowspan="1" colspan="1">2184/3405 (64.1%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Region</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Central/Eastern Europe</td><td align="left" rowspan="1" colspan="1">714/1574 (45.4%)</td><td align="left" rowspan="1" colspan="1">354/1203 (29.4%)</td><td align="left" rowspan="1" colspan="1">195/581 (33.6%)</td><td align="left" rowspan="1" colspan="1">798/3405 (23.4%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">East Asia</td><td align="left" rowspan="1" colspan="1">180/1574 (11.4%)</td><td align="left" rowspan="1" colspan="1">110/1203 (9.1%)</td><td align="left" rowspan="1" colspan="1">42/581 (7.2%)</td><td align="left" rowspan="1" colspan="1">246/3405 (7.2%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Indian subcontinent</td><td align="left" rowspan="1" colspan="1">147/1574 (9.3%)</td><td align="left" rowspan="1" colspan="1">140/1203 (11.6%)</td><td align="left" rowspan="1" colspan="1">43/581 (7.4%)</td><td align="left" rowspan="1" colspan="1">149/3405 (4.4%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Latin America</td><td align="left" rowspan="1" colspan="1">175/1574 (11.1%)</td><td align="left" rowspan="1" colspan="1">142/1203 (11.8%)</td><td align="left" rowspan="1" colspan="1">61/581 (10.5%)</td><td align="left" rowspan="1" colspan="1">381/3405 (11.2%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mediterranean basin</td><td align="left" rowspan="1" colspan="1">103/1574 (6.5%)</td><td align="left" rowspan="1" colspan="1">86/1203 (7.1%)</td><td align="left" rowspan="1" colspan="1">32/581 (5.5%)</td><td align="left" rowspan="1" colspan="1">318/3405 (9.3%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">North America</td><td align="left" rowspan="1" colspan="1">132/1574 (8.4%)</td><td align="left" rowspan="1" colspan="1">190/1203 (15.8%)</td><td align="left" rowspan="1" colspan="1">99/581 (17.0%)</td><td align="left" rowspan="1" colspan="1">821/3405 (24.1%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Western Europe/Scandinavia</td><td align="left" rowspan="1" colspan="1">112/1574 (7.1%)</td><td align="left" rowspan="1" colspan="1">158/1203 (13.1%)</td><td align="left" rowspan="1" colspan="1">95/581 (16.4%)</td><td align="left" rowspan="1" colspan="1">604/3405 (17.7%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Rest of world</td><td align="left" rowspan="1" colspan="1">11/1574 (0.7%)</td><td align="left" rowspan="1" colspan="1">23/1203 (1.9%)</td><td align="left" rowspan="1" colspan="1">14/581 (2.4%)</td><td align="left" rowspan="1" colspan="1">88/3405 (2.6%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Presentation characteristics</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hours from presentation to start of study drug</td><td align="left" rowspan="1" colspan="1">83.3 (45.5, 141.4)</td><td align="left" rowspan="1" colspan="1">109.0 (64.8, 159.2)</td><td align="left" rowspan="1" colspan="1">109.7 (69.2, 158.4)</td><td align="left" rowspan="1" colspan="1">118.0 (72.3, 165.8)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Killip class II&#x02013;IV on presentation</td><td align="left" rowspan="1" colspan="1">129/1572 (8.2%)</td><td align="left" rowspan="1" colspan="1">148/1202 (12.3%)</td><td align="left" rowspan="1" colspan="1">81/581 (13.9%)</td><td align="left" rowspan="1" colspan="1">467/3404 (13.7%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Disease classification</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Unstable angina/unknown</td><td align="left" rowspan="1" colspan="1">1291/1574 (82.0%)</td><td align="left" rowspan="1" colspan="1">165/1203 (13.7%)</td><td align="left" rowspan="1" colspan="1">0/581 (0.0%)</td><td align="left" rowspan="1" colspan="1">0/3405 (0.0%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">NSTEMI</td><td align="left" rowspan="1" colspan="1">283/1574 (18.0%)</td><td align="left" rowspan="1" colspan="1">1038/1203 (86.3%)</td><td align="left" rowspan="1" colspan="1">581/581 (100.0%)</td><td align="left" rowspan="1" colspan="1">3405/3405 (100.0%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Medical history</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Family history of CAD</td><td align="left" rowspan="1" colspan="1">421/1402 (30.0%)</td><td align="left" rowspan="1" colspan="1">361/1070 (33.7%)</td><td align="left" rowspan="1" colspan="1">162/522 (31.0%)</td><td align="left" rowspan="1" colspan="1">1064/2984 (35.7%)</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1">1347/1570 (85.8%)</td><td align="left" rowspan="1" colspan="1">991/1201 (82.5%)</td><td align="left" rowspan="1" colspan="1">491/581 (84.5%)</td><td align="left" rowspan="1" colspan="1">2720/3393 (80.2%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hyperlipidemia</td><td align="left" rowspan="1" colspan="1">925/1482 (62.4%)</td><td align="left" rowspan="1" colspan="1">711/1164 (61.1%)</td><td align="left" rowspan="1" colspan="1">334/565 (59.1%)</td><td align="left" rowspan="1" colspan="1">2175/3304 (65.8%)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes mellitus</td><td align="left" rowspan="1" colspan="1">598/1574 (38.0%)</td><td align="left" rowspan="1" colspan="1">488/1201 (40.6%)</td><td align="left" rowspan="1" colspan="1">244/581 (42.0%)</td><td align="left" rowspan="1" colspan="1">1309/3396 (38.5%)</td><td align="left" rowspan="1" colspan="1">0.214</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Current/recent smoking<xref ref-type="fn" rid="jah32181-note-0003">a</xref>
</td><td align="left" rowspan="1" colspan="1">268/1558 (17.2%)</td><td align="left" rowspan="1" colspan="1">231/1192 (19.4%)</td><td align="left" rowspan="1" colspan="1">119/573 (20.8%)</td><td align="left" rowspan="1" colspan="1">826/3363 (24.6%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior MI</td><td align="left" rowspan="1" colspan="1">697/1566 (44.5%)</td><td align="left" rowspan="1" colspan="1">559/1194 (46.8%)</td><td align="left" rowspan="1" colspan="1">260/576 (45.1%)</td><td align="left" rowspan="1" colspan="1">1408/3366 (41.8%)</td><td align="left" rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior PCI</td><td align="left" rowspan="1" colspan="1">521/1569 (33.2%)</td><td align="left" rowspan="1" colspan="1">422/1196 (35.3%)</td><td align="left" rowspan="1" colspan="1">176/578 (30.4%)</td><td align="left" rowspan="1" colspan="1">795/3372 (23.6%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior CABG</td><td align="left" rowspan="1" colspan="1">261/1572 (16.6%)</td><td align="left" rowspan="1" colspan="1">218/1203 (18.1%)</td><td align="left" rowspan="1" colspan="1">90/580 (15.5%)</td><td align="left" rowspan="1" colspan="1">632/3390 (18.6%)</td><td align="left" rowspan="1" colspan="1">0.149</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior PAD</td><td align="left" rowspan="1" colspan="1">92/1552 (5.9%)</td><td align="left" rowspan="1" colspan="1">89/1175 (7.6%)</td><td align="left" rowspan="1" colspan="1">43/572 (7.5%)</td><td align="left" rowspan="1" colspan="1">302/3333 (9.1%)</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior atrial fibrillation</td><td align="left" rowspan="1" colspan="1">126/1533 (8.2%)</td><td align="left" rowspan="1" colspan="1">106/1175 (9.0%)</td><td align="left" rowspan="1" colspan="1">50/565 (8.8%)</td><td align="left" rowspan="1" colspan="1">263/3296 (8.0%)</td><td align="left" rowspan="1" colspan="1">0.685</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior heart failure</td><td align="left" rowspan="1" colspan="1">304/1565 (19.4%)</td><td align="left" rowspan="1" colspan="1">178/1194 (14.9%)</td><td align="left" rowspan="1" colspan="1">98/576 (17.0%)</td><td align="left" rowspan="1" colspan="1">400/3376 (11.8%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior stroke</td><td align="left" rowspan="1" colspan="1">7/1571 (0.4%)</td><td align="left" rowspan="1" colspan="1">4/1198 (0.3%)</td><td align="left" rowspan="1" colspan="1">4/578 (0.7%)</td><td align="left" rowspan="1" colspan="1">24/3385 (0.7%)</td><td align="left" rowspan="1" colspan="1">0.414</td></tr><tr><td align="left" colspan="6" rowspan="1">Baseline risk assessment</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">GRACE risk score</td><td align="left" rowspan="1" colspan="1">116.0 (101.0, 130.0)</td><td align="left" rowspan="1" colspan="1">122.0 (106.0, 141.0)</td><td align="left" rowspan="1" colspan="1">128.0 (112.0, 147.0)</td><td align="left" rowspan="1" colspan="1">124.0 (108.0, 144.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">27.0 (24.5, 30.5)</td><td align="left" rowspan="1" colspan="1">27.2 (24.2, 31.0)</td><td align="left" rowspan="1" colspan="1">27.2 (24.6, 30.8)</td><td align="left" rowspan="1" colspan="1">27.3 (24.4, 30.8)</td><td align="left" rowspan="1" colspan="1">0.485</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Systolic blood pressure, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">130.0 (120.0, 140.0)</td><td align="left" rowspan="1" colspan="1">130.0 (117.0, 140.0)</td><td align="left" rowspan="1" colspan="1">126.0 (118.0, 138.0)</td><td align="left" rowspan="1" colspan="1">125.0 (115.0, 138.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Heart rate, bpm</td><td align="left" rowspan="1" colspan="1">68.5 (62.0, 76.0)</td><td align="left" rowspan="1" colspan="1">69.0 (62.0, 76.0)</td><td align="left" rowspan="1" colspan="1">68.0 (60.0, 76.0)</td><td align="left" rowspan="1" colspan="1">69.0 (62.0, 76.0)</td><td align="left" rowspan="1" colspan="1">0.491</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hemoglobin, g/dL</td><td align="left" rowspan="1" colspan="1">13.6 (12.6, 14.6)</td><td align="left" rowspan="1" colspan="1">13.4 (12.3, 14.5)</td><td align="left" rowspan="1" colspan="1">13.6 (12.4, 14.7)</td><td align="left" rowspan="1" colspan="1">13.5 (12.4, 14.7)</td><td align="left" rowspan="1" colspan="1">0.104</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Serum creatinine, mg/dL</td><td align="left" rowspan="1" colspan="1">1.0 (0.8, 1.1)</td><td align="left" rowspan="1" colspan="1">1.0 (0.8, 1.2)</td><td align="left" rowspan="1" colspan="1">1.0 (0.9, 1.2)</td><td align="left" rowspan="1" colspan="1">1.0 (0.8, 1.2)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" colspan="6" rowspan="1">At randomization</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.323</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Prasugrel</td><td align="left" rowspan="1" colspan="1">767/1574 (48.7%)</td><td align="left" rowspan="1" colspan="1">585/1203 (48.6%)</td><td align="left" rowspan="1" colspan="1">276/581 (47.5%)</td><td align="left" rowspan="1" colspan="1">1725/3405 (50.7%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Clopidogrel</td><td align="left" rowspan="1" colspan="1">807/1574 (51.3%)</td><td align="left" rowspan="1" colspan="1">618/1203 (51.4%)</td><td align="left" rowspan="1" colspan="1">305/581 (52.5%)</td><td align="left" rowspan="1" colspan="1">1680/3405 (49.3%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Clopidogrel strata</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">No clopidogrel</td><td align="left" rowspan="1" colspan="1">123/1574 (7.8%)</td><td align="left" rowspan="1" colspan="1">36/1203 (3.0%)</td><td align="left" rowspan="1" colspan="1">22/581 (3.8%)</td><td align="left" rowspan="1" colspan="1">92/3405 (2.7%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Clopidogrel started in hospital &#x02264;72&#x000a0;hours</td><td align="left" rowspan="1" colspan="1">905/1574 (57.5%)</td><td align="left" rowspan="1" colspan="1">798/1203 (66.3%)</td><td align="left" rowspan="1" colspan="1">421/581 (72.5%)</td><td align="left" rowspan="1" colspan="1">2759/3405 (81.0%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Home clopidogrel</td><td align="left" rowspan="1" colspan="1">546/1574 (34.7%)</td><td align="left" rowspan="1" colspan="1">369/1203 (30.7%)</td><td align="left" rowspan="1" colspan="1">138/581 (23.8%)</td><td align="left" rowspan="1" colspan="1">554/3405 (16.3%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Prerandomization procedures</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Angiography performed</td><td align="left" rowspan="1" colspan="1">555/1574 (35.3%)</td><td align="left" rowspan="1" colspan="1">568/1203 (47.2%)</td><td align="left" rowspan="1" colspan="1">256/581 (44.1%)</td><td align="left" rowspan="1" colspan="1">1941/3405 (57.0%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" colspan="6" rowspan="1">Concomitant medications at randomization</td></tr><tr><td align="left" style="padding-left:10%" colspan="6" rowspan="1">Aspirin daily dose</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003c;100&#x000a0;mg</td><td align="left" rowspan="1" colspan="1">470/1574 (29.9%)</td><td align="left" rowspan="1" colspan="1">406/1203 (33.7%)</td><td align="left" rowspan="1" colspan="1">182/581 (31.3%)</td><td align="left" rowspan="1" colspan="1">1116/3405 (32.8%)</td><td align="left" rowspan="1" colspan="1">0.112</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">100 to 250&#x000a0;mg</td><td align="left" rowspan="1" colspan="1">943/1574 (59.9%)</td><td align="left" rowspan="1" colspan="1">628/1203 (52.2%)</td><td align="left" rowspan="1" colspan="1">308/581 (53.0%)</td><td align="left" rowspan="1" colspan="1">1658/3405 (48.7%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003e;250&#x000a0;mg</td><td align="left" rowspan="1" colspan="1">86/1574 (5.5%)</td><td align="left" rowspan="1" colspan="1">89/1203 (7.4%)</td><td align="left" rowspan="1" colspan="1">56/581 (9.6%)</td><td align="left" rowspan="1" colspan="1">396/3405 (11.6%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x003b2;&#x02010;Blocker</td><td align="left" rowspan="1" colspan="1">1248/1574 (79.3%)</td><td align="left" rowspan="1" colspan="1">947/1203 (78.7%)</td><td align="left" rowspan="1" colspan="1">468/581 (80.6%)</td><td align="left" rowspan="1" colspan="1">2753/3405 (80.9%)</td><td align="left" rowspan="1" colspan="1">0.339</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ACE&#x02010;I/ARB</td><td align="left" rowspan="1" colspan="1">1173/1574 (74.5%)</td><td align="left" rowspan="1" colspan="1">883/1203 (73.4%)</td><td align="left" rowspan="1" colspan="1">446/581 (76.8%)</td><td align="left" rowspan="1" colspan="1">2635/3405 (77.4%)</td><td align="left" rowspan="1" colspan="1">0.018</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Statin</td><td align="left" rowspan="1" colspan="1">1287/1574 (81.8%)</td><td align="left" rowspan="1" colspan="1">1016/1203 (84.5%)</td><td align="left" rowspan="1" colspan="1">482/581 (83.0%)</td><td align="left" rowspan="1" colspan="1">2945/3405 (86.5%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Proton pump inhibitor</td><td align="left" rowspan="1" colspan="1">355/1574 (22.6%)</td><td align="left" rowspan="1" colspan="1">308/1203 (25.6%)</td><td align="left" rowspan="1" colspan="1">185/581 (31.8%)</td><td align="left" rowspan="1" colspan="1">982/3405 (28.8%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="jah32181-note-0002"><p>Data presented as n/N (%) or median (25th, 75th percentile). ACE&#x02010;I/ARB indicates angiotensin&#x02010;converting enzyme inhibitor/angiotensin receptor blocker; bpm, beats per minute; CABG, coronary artery bypass graft; CAD, coronary artery disease; GRACE, Global Registry of Acute Coronary Events; MI, myocardial infarction; NSTEMI, non&#x02010;ST&#x02010;segment elevation myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; ULN, upper limit of normal.</p></fn><fn id="jah32181-note-0003"><label>a</label><p>Smoking within 30&#x000a0;days of randomization.</p></fn></table-wrap-foot></table-wrap></sec><sec id="jah32181-sec-0013"><title>Ischemic Outcomes According to Peak Troponin</title><p>Table&#x000a0;<xref rid="jah32181-tbl-0002" ref-type="table-wrap">2</xref> shows the number of 30&#x02010;month ischemic outcome events and Kaplan&#x02013;Meier event rates across peak troponin categories. Figure&#x000a0;<xref rid="jah32181-fig-0001" ref-type="fig">1</xref> displays corresponding Kaplan&#x02013;Meier event rate curves. Trends for increasing event rates with increasing peak troponin ratios were statistically significant for all end points. The relationship was linear for 30&#x02010;month all&#x02010;cause mortality but appeared to increase and then plateau at peak troponin ratios &#x02265;3&#x000d7;ULN for the composite end points. The greatest difference in event rates was between peak troponin ratios &#x0003c;1&#x000d7;ULN and any peak troponin ratio &#x02265;1&#x000d7;ULN during early follow&#x02010;up. Through 30&#x000a0;months, event rates for patients with peak troponin ratios &#x02265;5&#x000d7;ULN were more than twice as high as rates for patients with peak troponin ratios &#x0003c;1&#x000d7;ULN.</p><table-wrap id="jah32181-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Thirty&#x02010;Month Ischemic Event Rates According to 48&#x02010;Hour Peak Troponin Level</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Peak Troponin Level as Ratio of ULN</th><th align="left" rowspan="2" valign="top" colspan="1">
<italic>P</italic> Value<xref ref-type="fn" rid="jah32181-note-0005">a</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">&#x0003c;1x (n=1574)</th><th align="left" valign="top" rowspan="1" colspan="1">1x to &#x0003c;3x (n=1203)</th><th align="left" valign="top" rowspan="1" colspan="1">3x to &#x0003c;5x (n=581)</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;5x (n=3405)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Cardiovascular death, MI, or stroke</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No. of events</td><td align="left" rowspan="1" colspan="1">118</td><td align="left" rowspan="1" colspan="1">172</td><td align="left" rowspan="1" colspan="1">104</td><td align="left" rowspan="1" colspan="1">607</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">KM event rate (95% CI)</td><td align="left" rowspan="1" colspan="1">11.3 (9.1&#x02013;13.5)</td><td align="left" rowspan="1" colspan="1">18.4 (15.3&#x02013;21.4)</td><td align="left" rowspan="1" colspan="1">26.6 (20.9&#x02013;32.3)</td><td align="left" rowspan="1" colspan="1">25.1 (23.0&#x02013;27.1)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cardiovascular death</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No. of events</td><td align="left" rowspan="1" colspan="1">62</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">297</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">KM event rate (95% CI)</td><td align="left" rowspan="1" colspan="1">5.8 (4.2&#x02013;7.3)</td><td align="left" rowspan="1" colspan="1">9.6 (7.0&#x02013;12.3)</td><td align="left" rowspan="1" colspan="1">10.8 (6.6&#x02013;15.0)</td><td align="left" rowspan="1" colspan="1">12.8 (11.1&#x02013;14.4)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial infarction</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No. of events</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">102</td><td align="left" rowspan="1" colspan="1">72</td><td align="left" rowspan="1" colspan="1">364</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">KM event rate (95% CI)</td><td align="left" rowspan="1" colspan="1">6.4 (4.6&#x02013;8.1)</td><td align="left" rowspan="1" colspan="1">10.4 (8.4&#x02013;12.4)</td><td align="left" rowspan="1" colspan="1">17.6 (13.1&#x02013;22.0)</td><td align="left" rowspan="1" colspan="1">15.6 (13.8&#x02013;17.3)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cardiovascular death or MI</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No. of events</td><td align="left" rowspan="1" colspan="1">111</td><td align="left" rowspan="1" colspan="1">157</td><td align="left" rowspan="1" colspan="1">97</td><td align="left" rowspan="1" colspan="1">569</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">KM event rate (95% CI)</td><td align="left" rowspan="1" colspan="1">10.6 (8.5&#x02013;12.8)</td><td align="left" rowspan="1" colspan="1">16.8 (13.8&#x02013;19.8)</td><td align="left" rowspan="1" colspan="1">25.0 (19.4&#x02013;30.6)</td><td align="left" rowspan="1" colspan="1">23.5 (21.4&#x02013;25.5)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stroke</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No. of events</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">KM event rate (95% CI)</td><td align="left" rowspan="1" colspan="1">1.2 (0.4&#x02013;2.0)</td><td align="left" rowspan="1" colspan="1">2.8 (1.5&#x02013;4.1)</td><td align="left" rowspan="1" colspan="1">1.8 (0.5&#x02013;3.2)</td><td align="left" rowspan="1" colspan="1">3.3 (2.4&#x02013;4.3)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">All&#x02010;cause death</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No. of events</td><td align="left" rowspan="1" colspan="1">83</td><td align="left" rowspan="1" colspan="1">102</td><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">362</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">KM event rate (95% CI)</td><td align="left" rowspan="1" colspan="1">7.3 (5.7&#x02013;9.0)</td><td align="left" rowspan="1" colspan="1">11.8 (9.1&#x02013;14.5)</td><td align="left" rowspan="1" colspan="1">14.7 (10.3&#x02013;19.0)</td><td align="left" rowspan="1" colspan="1">14.8 (13.2&#x02013;16.5)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="jah32181-note-0004"><p>KM indicates Kaplan&#x02013;Meier; MI, myocardial infarction; No., number; ULN, upper limit of normal.</p></fn><fn id="jah32181-note-0005"><label>a</label><p>Two&#x02010;sided <italic>P</italic> value based on the log&#x02010;rank test.</p></fn></table-wrap-foot></table-wrap><fig fig-type="Figure" xml:lang="en" id="jah32181-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Cumulative Kaplan&#x02013;Meier estimates of 30&#x02010;month ischemic outcomes by 48&#x02010;hour peak troponin elevation. For visualization of the numerical results presented in Table&#x000a0;<xref rid="jah32181-tbl-0002" ref-type="table-wrap">2</xref>, Kaplan&#x02013;Meier failure curves are presented for each efficacy end point. See Table&#x000a0;<xref rid="jah32181-tbl-0002" ref-type="table-wrap">2</xref> for relevant log&#x02010;rank <italic>P</italic> values. MI indicates myocardial infarction; ULN, upper limit of normal.</p></caption><graphic id="nlm-graphic-1" xlink:href="JAH3-6-e005334-g001"/></fig><p>Table&#x000a0;<xref rid="jah32181-tbl-0003" ref-type="table-wrap">3</xref> displays unadjusted and adjusted hazard ratios for 30&#x02010;month ischemic outcomes per unit increase in peak troponin ratio, modeled as a linear spline. The graphic representation of this relationship for the primary efficacy end point is displayed in Figure&#x000a0;<xref rid="jah32181-sup-0001" ref-type="supplementary-material">S1</xref>A and <xref rid="jah32181-sup-0001" ref-type="supplementary-material">S1</xref>B. In unadjusted analyses, increases in peak troponin ratio were strongly associated with each outcome up to 3&#x000d7;ULN; beyond this, the risk of ischemic events remained relatively constant as peak troponin ratios increased. Results were consistent after adjustment for baseline characteristics, except that the association with cardiovascular death was no longer significant. Note, the upper segment of the troponin linear spline (ratios &#x0003e;3&#x000d7;ULN) is not presented in Table&#x000a0;<xref rid="jah32181-tbl-0003" ref-type="table-wrap">3</xref> as all associations with outcomes are nonsignificant.</p><table-wrap id="jah32181-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Unadjusted and Adjusted Hazard Ratios for 30&#x02010;Month Ischemic Outcomes According to 48&#x02010;Hour Peak Troponin Elevation</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Unadjusted HR (95% CI)<xref ref-type="fn" rid="jah32181-note-0007">a</xref>
</th><th align="left" valign="top" rowspan="1" colspan="1">Adjusted HR (95% CI)<xref ref-type="fn" rid="jah32181-note-0007">a</xref>
</th><th align="left" valign="top" rowspan="1" colspan="1">Peak Troponin&#x000d7;Treatment Interaction <italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Cardiovascular death, MI, stroke</td><td align="left" rowspan="1" colspan="1">1.350 (1.263&#x02013;1.442)</td><td align="left" rowspan="1" colspan="1">1.182 (1.066&#x02013;1.311)</td><td align="left" rowspan="1" colspan="1">0.483</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiovascular death or MI</td><td align="left" rowspan="1" colspan="1">1.347 (1.257&#x02013;1.443)</td><td align="left" rowspan="1" colspan="1">1.183 (1.062&#x02013;1.318)</td><td align="left" rowspan="1" colspan="1">0.433</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiovascular death</td><td align="left" rowspan="1" colspan="1">1.291 (1.175&#x02013;1.419)</td><td align="left" rowspan="1" colspan="1">1.090 (0.942&#x02013;1.263)</td><td align="left" rowspan="1" colspan="1">0.371</td></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial infarction</td><td align="left" rowspan="1" colspan="1">1.411 (1.292&#x02013;1.541)</td><td align="left" rowspan="1" colspan="1">1.238 (1.081&#x02013;1.419)</td><td align="left" rowspan="1" colspan="1">0.413</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroke</td><td align="left" rowspan="1" colspan="1">1.387 (1.136&#x02013;1.695)</td><td align="left" rowspan="1" colspan="1">0.998 (0.996&#x02013;1.001)<xref ref-type="fn" rid="jah32181-note-0008">b</xref>
</td><td align="left" rowspan="1" colspan="1">0.191</td></tr><tr><td align="left" rowspan="1" colspan="1">All&#x02010;cause mortality</td><td align="left" rowspan="1" colspan="1">1.282 (1.179&#x02013;1.393)</td><td align="left" rowspan="1" colspan="1">1.001 (1.000&#x02013;1.001)<xref ref-type="fn" rid="jah32181-note-0008">b</xref>
</td><td align="left" rowspan="1" colspan="1">0.234</td></tr></tbody></table><table-wrap-foot><fn id="jah32181-note-0006"><p>HR indicates hazard ratio; MI, myocardial infarction.</p></fn><fn id="jah32181-note-0007"><label>a</label><p>Per 1&#x000a0;unit increase in peak troponin/upper limit of normal ratio.</p></fn><fn id="jah32181-note-0008"><label>b</label><p>Peak troponin elevation modeled linearly as the assumption of linearity was satisfied.</p></fn></table-wrap-foot></table-wrap><p>Table&#x000a0;<xref rid="jah32181-tbl-0003" ref-type="table-wrap">3</xref> also shows that there were no statistically significant interactions between peak troponin ratio and study treatment for any of the ischemic outcomes. The graphic representation of this relationship is displayed in Figure&#x000a0;<xref rid="jah32181-sup-0001" ref-type="supplementary-material">S2</xref>. In a subgroup analysis assessing this relationship among patients with angiographically proven coronary disease, the interaction between peak troponin ratio, study treatment, and either combined end point or all&#x02010;cause mortality also lacked statistical significance. These results remained unchanged after adjustment for time from patient presentation to administration of study drug.</p></sec><sec id="jah32181-sec-0014"><title>Peak Troponin and Platelet Function</title><p>Among patients enrolled in the TRILOGY ACS Platelet Function Substudy, 1810 (70.6%) had necessary measurements to compute peak troponin/ULN ratios. Baseline characteristics by peak troponin ratio category are shown in Table&#x000a0;<xref rid="jah32181-sup-0001" ref-type="supplementary-material">S6</xref>. Compared with other groups, patients with peak troponin ratios &#x0003c;1xULN were younger, more often from Central/Eastern Europe, and less likely to be current/prior smokers or have a family history of coronary artery disease or hyperlipidemia. Additionally, they were less likely to have undergone angiography prior to randomization. Diabetes mellitus prevalence was similar across groups.</p><p>As displayed in Figure&#x000a0;<xref rid="jah32181-fig-0002" ref-type="fig">2</xref>, there was no relationship between peak troponin and PRU among patients with angiographically proven coronary artery disease. Results remain unchanged even after adjustment for age group (&#x02265;75&#x000a0;years versus &#x0003c;75&#x000a0;years), clopidogrel stratum at randomization, randomized treatment assignment, and time from patient presentation to start of study drug.</p><fig fig-type="Figure" xml:lang="en" id="jah32181-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Forty&#x02010;eight&#x02010;hour peak troponin ratio and 30&#x02010;day platelet reactivity unit (<styled-content style="fixed-case">PRU</styled-content>). For patients enrolled in the Platelet Function Substudy, a box plot is used to assess the unadjusted association of peak troponin elevation with 30&#x02010;day <styled-content style="fixed-case">PRU</styled-content>, as well as the interaction with study treatment (<italic>P</italic>&#x0003c;0.001). ULN indicates upper limit of normal.</p></caption><graphic id="nlm-graphic-3" xlink:href="JAH3-6-e005334-g002"/></fig></sec></sec><sec id="jah32181-sec-0015"><title>Discussion</title><p>This analysis of TRILOGY ACS demonstrated that among NSTE ACS patients selected for medical management, including dual antiplatelet therapy with a P2Y12 antagonist, there was a graded relationship of increasing peak troponin with long&#x02010;term ischemic events. Event rates at 30&#x000a0;months for patients with troponin &#x02265;5&#x000d7;ULN were more than twice those for patients with peak troponin &#x0003c;1&#x000d7;ULN. There was no apparent incremental benefit of treatment with prasugrel versus clopidogrel according to peak troponin ratio among medically managed patients with NSTE ACS.</p><sec id="jah32181-sec-0016"><title>Peak Troponin and Long&#x02010;Term Outcomes</title><p>Since the introduction of troponin testing in the early 1990s, its role has evolved from MI diagnosis to include risk stratification following ACS. It is known from previous analyses, including FRISC (Fragmin during Instability in Coronary Artery Disease) and TACTICS&#x02010;TIMI 18 (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy&#x02014;Thrombolysis in Myocardial Infarction 18) that patients with NSTE ACS who have troponin elevations above the ULN at admission are at higher risk for death and recurrent ischemic events.<xref rid="jah32181-bib-0002" ref-type="ref">2</xref>, <xref rid="jah32181-bib-0008" ref-type="ref">8</xref>, <xref rid="jah32181-bib-0009" ref-type="ref">9</xref> Furthermore, through additional analyses of trials such as GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) IIa, there is a well&#x02010;characterized relationship between the magnitude of troponin elevation and outcomes among patients with NSTE ACS.<xref rid="jah32181-bib-0001" ref-type="ref">1</xref> Troponin elevation can also identify which patients are most likely to benefit from aggressive antithrombotic therapy and an early invasive strategy.<xref rid="jah32181-bib-0008" ref-type="ref">8</xref>, <xref rid="jah32181-bib-0009" ref-type="ref">9</xref>
</p><p>Recently, a secondary analysis of the TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) trial, a study designed to examine the effect of vorapaxar (a protease&#x02010;activated receptor&#x02010;1 antagonist) versus placebo in NSTE ACS, identified a differential relationship between the magnitude of troponin elevation and 2&#x02010;year mortality among patients treated with and without revascularization. In a subset of patients included in TRACER who did not undergo revascularization, increasing levels of peak cardiac troponin were associated with increasing long&#x02010;term mortality (<italic>P</italic>=0.001). This relationship was not observed in those who underwent revascularization (<italic>P</italic>=0.23).<xref rid="jah32181-bib-0010" ref-type="ref">10</xref>
</p><p>The graded relationship of increasing peak troponin with ischemic events that we observed was consistent with this observation and prior studies evaluating troponin elevation as a prognostic indicator among patients with NSTE ACS. However, TRILOGY ACS provided the unique opportunity to establish this relationship over a long&#x02010;term (30&#x02010;month) follow&#x02010;up period among patients who were medically managed with P2Y12 inhibitor therapy. Thus, the results of this analysis extend our understanding of the relationship of troponin with risk to long&#x02010;term follow&#x02010;up in the important population of medically managed NSTE ACS patients in the contemporary era of more potent P2Y12 inhibitor therapy. Our analyses demonstrate that despite advances in other medical therapy acutely and in secondary prevention, higher peak troponin values portend worse ischemic outcomes.</p></sec><sec id="jah32181-sec-0017"><title>Peak Troponin and Effect of More Potent Antiplatelet Therapy</title><p>Substudies of several randomized clinical trials showed that the treatment effect of glycoprotein IIb/IIIa antagonists was amplified among patients with baseline troponin elevation, but there was no evident benefit among those without.<xref rid="jah32181-bib-0011" ref-type="ref">11</xref>, <xref rid="jah32181-bib-0012" ref-type="ref">12</xref>, <xref rid="jah32181-bib-0013" ref-type="ref">13</xref> These findings were consistent across studies despite significant differences in patient populations, highlighting the importance of troponin elevation in identifying high&#x02010;risk patients who may benefit from more potent antiplatelet therapy.<xref rid="jah32181-bib-0011" ref-type="ref">11</xref> Given these observations and our results correlating troponin and rates of adverse cardiovascular events, it might be anticipated that higher&#x02010;risk medically managed patients with greater peak troponin levels would also benefit preferentially from more potent antiplatelet therapy. However, we observed no such interaction of peak troponin level with more potent dual antiplatelet therapy among patients assigned to prasugrel compared with clopidogrel. This was consistent among the subset of patients with angiographically proven coronary disease who were medically managed in TRILOGY ACS. Thus, it is unlikely that inclusion of patients with troponin elevation unrelated to atherosclerotic coronary disease significantly influenced our analysis.</p><p>A number of considerations may contribute to our observations. Because this is a secondary analysis, it was not powered to detect an effect of more potent P2Y12 inhibition according to peak troponin values. Further, whereas the PARAGON&#x02010;B (Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B) study assessed a glycoprotein IIb/IIIa inhibitor (steady&#x02010;state platelet aggregation inhibition &#x0003e;90%) versus placebo, neither prasugrel (50%) nor clopidogrel (30%) achieve that level of platelet aggregation inhibition, and they were compared head&#x02010;to&#x02010;head instead of against placebo.<xref rid="jah32181-bib-0014" ref-type="ref">14</xref>, <xref rid="jah32181-bib-0015" ref-type="ref">15</xref> Together these features of trial design may have contributed to the differential findings. Additionally, participants in TRILOGY ACS were randomized to prasugrel or clopidogrel &#x02248;4.5&#x000a0;days after their index clinical event and could be enrolled up to 10&#x000a0;days after the index event.<xref rid="jah32181-bib-0005" ref-type="ref">5</xref> It is possible that the benefit of more potent antiplatelet therapy may be related to the timing of therapy initiation relative to myocardial ischemia onset (which was much earlier in PARAGON&#x02010;B), and particularly that patients with completed infarction by this time point may not benefit from more potent antiplatelet therapy. Additionally, prior evaluations of more potent antiplatelet therapies primarily focused on patients who underwent an invasive treatment strategy. It is possible that the benefit of more potent antiplatelet therapy seen in prior studies may have been derived from reduced periprocedural adverse ischemic outcomes. Finally, it is possible that bleeding complications may have attenuated the benefit of more potent antiplatelet therapy.</p></sec><sec id="jah32181-sec-0018"><title>Peak Troponin and Platelet Reactivity</title><p>A substudy of TRILOGY ACS evaluated the effects of prasugrel and clopidogrel on serial PRU assessments. This analysis revealed lower platelet reactivity with prasugrel compared with clopidogrel; however, there was no difference in ischemic outcomes by treatment assignment.<xref rid="jah32181-bib-0004" ref-type="ref">4</xref>, <xref rid="jah32181-bib-0005" ref-type="ref">5</xref> Our exploratory analysis of the TRILOGY ACS Platelet Function Substudy revealed that the effect of treatment on platelet inhibition (as assessed by 30&#x02010;day PRU values) did not vary substantially based on peak troponin value.</p></sec><sec id="jah32181-sec-0019"><title>Strengths and Limitations</title><p>This secondary analysis of TRILOGY ACS demonstrates a novel correlation between troponin elevation and prognosis in a study sample selected for medical management of NSTE ACS. One of the strengths of our analysis is that it used data collected as part of a large, multinational, randomized trial, which enhances data consistency and eliminates bias in the assessment of overall treatment effects. Because of the large number of subjects, the results are statistically robust. However, because these results are drawn from a patient population selected for a randomized clinical trial, they may not be generalizable to the broader population of medically managed patients in general practice. Troponin values used for our analysis were collected up to 48&#x000a0;hours after presentation, consistent with contemporary clinical practice. It is possible that by limiting our analysis to values within 48&#x000a0;hours of presentation, a higher peak value could have been missed, but this rule was applied consistently to all patients. Peak troponin data within 48&#x000a0;hours were not available in about 25% of study participants, eliminating this group from our analysis. Although there were differences between those included or not, most were modest and would not be expected to alter the relationships we observed (Table&#x000a0;<xref rid="jah32181-sup-0001" ref-type="supplementary-material">S5</xref>). Troponin assays were not standardized across participating sites. Thus, they reflect a wide variety of individual assays with variable assay performance characteristics, and potentially varying site&#x02010;specific ULNs for the same assay. However, this reflects the state of actual clinical practice, and we attempted to account for this by normalizing the reported values using a ratio of the reported value to the ULN reported for the assay. This variability and resultant &#x0201c;noise&#x0201d; introduced would be expected to result in an underestimation of the relationship between increasing troponin level and outcomes. Additionally, it is possible that some patients with elevated troponin levels who were included in TRILOGY ACS did not have significant coronary artery disease. In this case, the true association of troponin with long&#x02010;term ischemic outcomes may have been underestimated. Of the patients who underwent angiography, however, very few had absence of obstructive coronary disease, and when we excluded those patients from our analyses, there were no differences in our findings. Although designed to evaluate medically managed patients, a small number of patients (7.1%) underwent postindex revascularization at a median of 120.5&#x000a0;days after the index event. Because of the infrequency of downstream revascularization in our study sample and that it occurred late relative to the time of troponin sampling, we believe the commitment to an initial medical management strategy was met and that it is unlikely that our results were significantly affected. Finally, it is possible that because we defined peak troponin using values collected within 48&#x000a0;hours after the index event, the true peak troponin value was missed. However, it is important to note that the impact of missing the true peak would tend to underestimate the relationship between peak troponin level and adverse outcomes. Despite its limitations, our analysis shows the prognostic importance of higher levels of troponin for long&#x02010;term outcomes among medically managed patients with NSTE ACS, even in the setting of treatment with modern, potent antiplatelet agents, and the effect is not related to the degree of platelet inhibition as assessed by the P2Y12 assay.</p></sec></sec><sec id="jah32181-sec-0020"><title>Conclusion</title><p>Among NSTE ACS patients selected for medical management, there was a graded relationship of increasing peak troponin with long&#x02010;term ischemic events, but no heterogeneity of treatment effect for prasugrel versus clopidogrel (clinical or PRU&#x02010;based) according to 48&#x02010;hour peak troponin level.</p></sec><sec id="jah32181-sec-0021"><title>Sources of Funding</title><p>The TRILOGY ACS study was supported by Daiichi Sankyo Incorporated and Eli Lilly and Company.</p></sec><sec id="jah32181-sec-0022"><title>Disclosures</title><p>Newby has reported all potential conflicts at <ext-link ext-link-type="uri" xlink:href="https://www.dcri.org/about-us/conflict-of-interest">https://www.dcri.org/about-us/conflict-of-interest</ext-link>. L&#x000fc;scher reports grants from AstraZeneca and from Eli Lilly during the conduct of the study. White reports grants from Sanofi Aventis, Eli Lilly and Company, National Institute of Health, and Merck Sharpe &#x00026; Dohm, grants and personal fees from AstraZeneca, grants from GlaxoSmithKline, Omthera Pharmaceuticals, Pfizer New Zealand, Intarcia Therapeutics Inc., Elsai Inc., DalGen Products and Services, and Daiichi Sankyo Pharma Development, outside the submitted work. Ohman reports receiving grant support and travel expenses from Daiichi Sankyo and Eli Lilly, consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol&#x02010;Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Liposcience, Merck, Pozen, Hoffmann&#x02010;La Roche, Sanofi&#x02010;Aventis, The Medicines Company, and Web MD; grant support from Gilead Sciences; and lecture fees from Gilead Sciences, Boehringer Ingelheim, and The Medicines Company. Roe reports research grants from Eli Lilly and Company, Janseen Pharmaceuticals, Sanofi&#x02010;Aventis, Daiichi&#x02010;Sankyo, Familial Hypercholesterolemia Foundation, and Ferring Pharmaceuticals; educational activities or lectures for Amgen and Bristol&#x02010;Myers Squibb; consulting or other services for AstraZeneca, Eli Lilly and Company, Merck &#x00026; Co., Elsevier Publishers, Amgen, Boehringer&#x02010;Ingelheim, and PriMed. All conflicts of interest are listed at <ext-link ext-link-type="uri" xlink:href="https://www.dcri.org/about-us/conflict-of-interest">https://www.dcri.org/about-us/conflict-of-interest</ext-link>. Hamm reports personal fees from GSK, during the conduct of the study; and personal fees from BRAHMS, outside the submitted work. The remaining authors have no disclosures to report.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="jah32181-sup-0001"><caption><p>
<bold>Data S1.</bold> TRILOGY ACS Adjustment Models.</p><p>
<bold>Table&#x000a0;S1.</bold> Censoring Scheme&#x000a0;for the Primary End Point (Cardiovascular Death, Myocardial Infarction, or Stroke) and for Nonfatal Secondary End Points</p><p>
<bold>Table&#x000a0;S2.</bold> Censoring Scheme&#x000a0;for Cardiovascular Death or for All&#x02010;Cause Death</p><p>
<bold>Table&#x000a0;S3.</bold> Descriptive Statistics for Troponin</p><p>
<bold>Table&#x000a0;S4.</bold> TRILOGY ACS Efficacy and Bleeding Adjustment Models</p><p>
<bold>Table&#x000a0;S5.</bold> Baseline Characteristics of Included and Excluded Study Patients</p><p>
<bold>Table&#x000a0;S6.</bold> Baseline Characteristics According to 48&#x02010;Hour Peak Troponin Level in Platelet Function Substudy Participants</p><p>
<bold>Figure&#x000a0;S1.</bold> A, Estimated spline transformation and 95% CI for the relationship of troponin elevation and unadjusted rates of cardiovascular death, MI, or stroke through 30&#x000a0;months. B, Estimated spline transformation and 95% CI for the relationship of troponin elevation and adjusted rates of cardiovascular death, MI, or stroke through 30&#x000a0;months.</p><p>
<bold>Figure&#x000a0;S2.</bold> Estimated spline transformation and 95% CI for the relationship of troponin elevation and adjusted rates of cardiovascular death, myocardial infarction, or stroke through 30&#x000a0;months stratified by treatment.</p></caption><media xlink:href="JAH3-6-e005334-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list content-type="cited-references" id="jah32181-bibl-0001"><title>References</title><ref id="jah32181-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah32181-cit-0001">
<string-name>
<surname>Ohman</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Armstrong</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Christenson</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Granger</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Katus</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Hamm</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>O'Hanesian</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Wagner</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Kleiman</surname>
<given-names>NS</given-names>
</string-name>, <string-name>
<surname>Harrell</surname>
<given-names>FE</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Califf</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Topol</surname>
<given-names>EJ</given-names>
</string-name>. <article-title>Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators</article-title>. <source>N Engl J Med</source>. <year>1996</year>;<volume>335</volume>:<fpage>1333</fpage>&#x02013;<lpage>1341</lpage>.<pub-id pub-id-type="pmid">8857016</pub-id></mixed-citation></ref><ref id="jah32181-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah32181-cit-0002">
<string-name>
<surname>Lindahl</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Venge</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Wallentin</surname>
<given-names>L</given-names>
</string-name>. <article-title>Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group</article-title>. <source>Circulation</source>. <year>1996</year>;<volume>93</volume>:<fpage>1651</fpage>&#x02013;<lpage>1657</lpage>.<pub-id pub-id-type="pmid">8653870</pub-id></mixed-citation></ref><ref id="jah32181-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah32181-cit-0003">
<string-name>
<surname>Newby</surname>
<given-names>LK</given-names>
</string-name>, <string-name>
<surname>Christenson</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Ohman</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Armstrong</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>TD</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Hamm</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Katus</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Cianciolo</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Granger</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Topol</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Califf</surname>
<given-names>RM</given-names>
</string-name>. <article-title>Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO&#x02010;IIa Investigators</article-title>. <source>Circulation</source>. <year>1998</year>;<volume>98</volume>:<fpage>1853</fpage>&#x02013;<lpage>1859</lpage>.<pub-id pub-id-type="pmid">9799204</pub-id></mixed-citation></ref><ref id="jah32181-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah32181-cit-0004">
<string-name>
<surname>Gurbel</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Erlinge</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ohman</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Neely</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Neely</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Goodman</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Huber</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>MY</given-names>
</string-name>, <string-name>
<surname>Cornel</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Jakubowski</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>HD</given-names>
</string-name>, <string-name>
<surname>Fox</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Prabhakaran</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Armstrong</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Tantry</surname>
<given-names>US</given-names>
</string-name>, <string-name>
<surname>Roe</surname>
<given-names>MT</given-names>
</string-name>; <collab collab-type="authors">TRILOGY ACS Platelet Function Substudy Investigators</collab>
. <article-title>Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy</article-title>. <source>JAMA</source>. <year>2012</year>;<volume>308</volume>:<fpage>1785</fpage>&#x02013;<lpage>1794</lpage>.<pub-id pub-id-type="pmid">23117779</pub-id></mixed-citation></ref><ref id="jah32181-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah32181-cit-0005">
<string-name>
<surname>Roe</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Armstrong</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Fox</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>HD</given-names>
</string-name>, <string-name>
<surname>Prabhakaran</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Goodman</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Cornel</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Bhatt</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Clemmensen</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Martinez</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ardissino</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Nicolau</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Boden</surname>
<given-names>WE</given-names>
</string-name>, <string-name>
<surname>Gurbel</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Ruzyllo</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Dalby</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>McGuire</surname>
<given-names>DK</given-names>
</string-name>, <string-name>
<surname>Leiva&#x02010;Pons</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Parkhomenko</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gottlieb</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Topacio</surname>
<given-names>GO</given-names>
</string-name>, <string-name>
<surname>Hamm</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Pavlides</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Goudev</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Oto</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tseng</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Merkely</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Gasparovic</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Corbalan</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cintez&#x00103;</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>McLendon</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Winters</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>EB</given-names>
</string-name>, <string-name>
<surname>Lokhnygina</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Aylward</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Huber</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hochman</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Ohman</surname>
<given-names>EM</given-names>
</string-name>; <collab collab-type="authors">TRILOGY ACS Investigators</collab>
. <article-title>Prasugrel versus clopidogrel for acute coronary syndromes without revascularization</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>367</volume>:<fpage>1297</fpage>&#x02013;<lpage>1309</lpage>.<pub-id pub-id-type="pmid">22920930</pub-id></mixed-citation></ref><ref id="jah32181-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah32181-cit-0006">
<string-name>
<surname>Eagle</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Dabbous</surname>
<given-names>OH</given-names>
</string-name>, <string-name>
<surname>Pieper</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Goldberg</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Van de Werf</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Goodman</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Granger</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Steg</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Gore</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Budaj</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Avezum</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Flather</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Fox</surname>
<given-names>KA</given-names>
</string-name>; <collab collab-type="authors">GRACE Investigators</collab>
. <article-title>A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6&#x02010;month postdischarge death in an international registry</article-title>. <source>JAMA</source>. <year>2004</year>;<volume>291</volume>:<fpage>2727</fpage>&#x02013;<lpage>2733</lpage>.<pub-id pub-id-type="pmid">15187054</pub-id></mixed-citation></ref><ref id="jah32181-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah32181-cit-0007">
<string-name>
<surname>Stone</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Koo</surname>
<given-names>CY</given-names>
</string-name>. <article-title>Additive splines in statistics</article-title>. <source>Proc Stat Comp Sect Am Statist Assoc</source>. <year>1985</year> Available at: <ext-link ext-link-type="uri" xlink:href="http://www.markdiamond.com.au/download/Stone-and-Koo-1986-A4.pdf">http://www.markdiamond.com.au/download/Stone-and-Koo-1986-A4.pdf</ext-link>. Accessed April 4, 2017.</mixed-citation></ref><ref id="jah32181-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah32181-cit-0008">
<string-name>
<surname>Newby</surname>
<given-names>LK</given-names>
</string-name>, <string-name>
<surname>Goldmann</surname>
<given-names>BU</given-names>
</string-name>, <string-name>
<surname>Ohman</surname>
<given-names>EM</given-names>
</string-name>. <article-title>Troponin: an important prognostic marker and risk&#x02010;stratification tool in non&#x02010;ST&#x02010;segment elevation acute coronary syndromes</article-title>. <source>J Am Coll Cardiol</source>. <year>2003</year>;<volume>41</volume>:<fpage>31S</fpage>&#x02013;<lpage>36S</lpage>.<pub-id pub-id-type="pmid">12644338</pub-id></mixed-citation></ref><ref id="jah32181-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah32181-cit-0009">
<string-name>
<surname>Morrow</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Rifai</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Frey</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Vicari</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lakkis</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Robertson</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Hille</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>DeLucca</surname>
<given-names>PT</given-names>
</string-name>, <string-name>
<surname>DiBattiste</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Demopoulos</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Weintraub</surname>
<given-names>WS</given-names>
</string-name>, <string-name>
<surname>Braunwald</surname>
<given-names>E</given-names>
</string-name>; <collab collab-type="authors">TACTICS&#x02010;TIMI 18 Investigators</collab>
. <article-title>Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non&#x02010;ST elevation myocardial infarction: results from a randomized trial</article-title>. <source>JAMA</source>. <year>2001</year>;<volume>286</volume>:<fpage>2405</fpage>&#x02013;<lpage>2412</lpage>.<pub-id pub-id-type="pmid">11712935</pub-id></mixed-citation></ref><ref id="jah32181-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah32181-cit-0010">
<string-name>
<surname>Bagai</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Lokhnygina</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Harrington</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Armstrong</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Strony</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>HD</given-names>
</string-name>, <string-name>
<surname>Leonardi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Held</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Van de Werf</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Wallentin</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Tricoci</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Mahaffey</surname>
<given-names>KW</given-names>
</string-name>. <article-title>Magnitude of troponin elevation and long&#x02010;term clinical outcomes in acute coronary syndrome patients treated with and without revascularization</article-title>. <source>Circ Cardiovasc Interv</source>. <year>2015</year>;<volume>8</volume>:<fpage>e002314</fpage>.<pub-id pub-id-type="pmid">26025218</pub-id></mixed-citation></ref><ref id="jah32181-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah32181-cit-0011">
<string-name>
<surname>Newby</surname>
<given-names>LK</given-names>
</string-name>, <string-name>
<surname>Ohman</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Christenson</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Moliterno</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Harrington</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>HD</given-names>
</string-name>, <string-name>
<surname>Armstrong</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Van De Werf</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Pfisterer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hasselblad</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Califf</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Topol</surname>
<given-names>EJ</given-names>
</string-name>. <article-title>Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T&#x02010;positive status: the paragon&#x02010;B troponin T substudy</article-title>. <source>Circulation</source>. <year>2001</year>;<volume>103</volume>:<fpage>2891</fpage>&#x02013;<lpage>2896</lpage>.<pub-id pub-id-type="pmid">11413076</pub-id></mixed-citation></ref><ref id="jah32181-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah32181-cit-0012">
<string-name>
<surname>Hamm</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Heeschen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Goldmann</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Vahanian</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Adgey</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Miguel</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Rutsch</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Berger</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kootstra</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Simoons</surname>
<given-names>ML</given-names>
</string-name>. <article-title>Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators</article-title>. <source>N Engl J Med</source>. <year>1999</year>;<volume>340</volume>:<fpage>1623</fpage>&#x02013;<lpage>1629</lpage>.<pub-id pub-id-type="pmid">10341274</pub-id></mixed-citation></ref><ref id="jah32181-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah32181-cit-0013">
<string-name>
<surname>Heeschen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hamm</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Goldmann</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Deu</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Langenbrink</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>HD</given-names>
</string-name>. <article-title>Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management</article-title>. <source>Lancet</source>. <year>1999</year>;<volume>354</volume>:<fpage>1757</fpage>&#x02013;<lpage>1762</lpage>.<pub-id pub-id-type="pmid">10577636</pub-id></mixed-citation></ref><ref id="jah32181-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah32181-cit-0014">
<string-name>
<surname>Mukherjee</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mahaffey</surname>
<given-names>KW</given-names>
</string-name>, <string-name>
<surname>Moliterno</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Harrington</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Yadav</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Pieper</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Gallup</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Dyke</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Roe</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Berdan</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Lauer</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>M&#x000e4;ntt&#x000e4;ri</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>HD</given-names>
</string-name>, <string-name>
<surname>Califf</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Topol</surname>
<given-names>EJ</given-names>
</string-name>. <article-title>Promise of combined low&#x02010;molecular&#x02010;weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B)</article-title>. <source>Am Heart J</source>. <year>2002</year>;<volume>144</volume>:<fpage>995</fpage>&#x02013;<lpage>1002</lpage>.<pub-id pub-id-type="pmid">12486423</pub-id></mixed-citation></ref><ref id="jah32181-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah32181-cit-0015">
<string-name>
<surname>Wallentin</surname>
<given-names>L</given-names>
</string-name>. <article-title>P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use</article-title>. <source>Eur Heart J</source>. <year>2009</year>;<volume>30</volume>:<fpage>1964</fpage>&#x02013;<lpage>1977</lpage>.<pub-id pub-id-type="pmid">19633016</pub-id></mixed-citation></ref></ref-list></back></article>